Decision modeling to inform decision making: Seeing the wood for the trees

Medical Decision Making

Volumn 30, Issue 3, 2010, Pages

  Karnon, Jonathan ^a   Brennan, Alan ^b   Akehurst, Ron ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DRUG DERIVATIVE; TICLOPIDINE;

CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DECISION MAKING; ECONOMICS; HUMAN; METHODOLOGY; NOTE; REIMBURSEMENT;

CORONARY DISEASE; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 77952968644     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X10364245     Document Type: Article

References (10)

1. Goldman L., Gaspoz J. -M. Cost-effectiveness of clopidogrel: seeing through the smoke. Med Decis Making. 2008 ; 28: 803-809
2. Karnon J., Brennan A., Akehurst R. A critique and impact analysis of decision modeling assumptions. Med Decis Making. 2007 ; 27: 491-499.
3. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med. 2002 ; 346: 1800-1806.
4. Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) (Version 4.3), 2008. Available from: URL: http://www.pbs.gov.au/html/industry/ static/how-to-list-on-the-pbs/elements-of-the-listing-process/pbac-guidelines/ b-part-2
5. National Institute for Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal (reference N0515), 2004. Available from: URL: http://www.nice.org.uk/niceMedia/pdf/TAP-Methods.pdf
6. McCabe C. Guidance on good practice in cost-effectiveness modeling: is more needed ? Med Decis Making. 2007 ; 27: 350-351.
7. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff. 2001 ; 20: 104-114.
8. Laupacis A. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? Can Med Assoc J. 2002 ; 166: 44-47.
9. National Institute for Clinical Excellence (NICE). Bortezomib monotherapy for relapsed multiple myeloma. NICE Technology Appraisal Guidance, October 2007.
10. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics. 2006 ; 24 (11). 1157-1162.